The Advantages of Adding Hyaluronic Acid or Mannitol to Hypertonic Saline Inhalation Treatment in Cystic Fibrosis

Cazzarolli, C.; Tartali, C.; Pradal, Ugo

doi:10.1089/jamp.2016.1318

Cited by 4 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As expected, the main AEs reported were with HS, whereas HA+HS showed an improved safety profile, between those of HS and IS. These findings agree with previous studies conducted within cystic fibrosis, (8,11,14) and support the alternative use of HA+HS in bronchiectasis. The relatively low rate of AEs of HA+HS may also explain why it was chosen as the preferred saline solution by patients.…”

Section: Fig 2 (A-c)supporting

confidence: 92%

“…Previous studies conducted in cystic fibrosis showed greater tolerance and pleasantness in favor of HA+HS compared with HS alone. (8,11,14) So far, no studies have compared the effectiveness and tolerability of HA+HS and HS in adult outpatients with bronchiectasis. Improved tolerability with at least equal efficacy of HA+HS may improve patients' adherence, while hopefully improving chronic respiratory symptoms and quality of life (QoL) for patients with bronchiectasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial

Herrero-Cortina

Alcaraz

Vilaró

et al. 2018

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

show abstract

Section: Fig 2 (A-c)supporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial

Herrero-Cortina

Alcaraz

Vilaró

et al. 2018

Journal of Aerosol Medicine and Pulmonary Drug Delivery

View full text Add to dashboard Cite

show abstract

“…After screening 442 publications identified from the initial search, five were included in the final analysis (n=236 patients). [15][16][17][18][19] (Supplemental Figure S1 ) Study characteristics and baseline demographics have been summarized in Table 1. The percentage of males varied from 40.0 to 53.8% between studies.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis

Arshid,

Ullah,

Imran

et al. 2023

Canadian Journal of Respiratory Therapy

View full text Add to dashboard Cite

Background Inhaled hypertonic saline (HS) is an effective mucolytic agent in patients with cystic fibrosis (CF). However, adverse events can impair the clinical utility of hypertonic saline (HS) in this patient population. In this study, we aimed to investigate the effectiveness of hyaluronic acid (HA) in reducing these adverse events. Methods A literature search was conducted across three electronic databases (Medline, Cochrane Central, and EMBASE) from inception through February 2023. Randomized controlled trials (RCTs) assessing the impact of hyaluronic acid (HA) in reducing adverse events in patients taking hypertonic saline (HS) for CF were included in the analysis. Outcomes of interest included cough, throat irritation, unpleasant taste, and FEV1. Evaluations were reported as risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CI). The Cochrane Risk of Bias Tool (CRBT) was employed to assess the quality of RCTs. The New Castle Ottawa Scale was used to assess the quality of observational studies. Results From the 1960 articles retrieved from the initial search, five relevant studies (n=236 patients) were included in the final analysis. Compared with patients only on HS, patients with HS and HA were significantly less likely to experience cough (RR: 0.45; 95% CI, 0.28–0.72, p=0.001), throat irritation (RR: 0.43; 95% CI, 0.22–0.81, p= 0.009), and unpleasant smell (RR: 0.43; 95% CI, 0.23 – 0.80, p=0.09). In addition, patients with HS with HA had significantly less forced expiratory volume (FEV1) (MD: -2.97; 95% CI, -3.79—2.15, p=0.52) compared to patients only on HS. Discussion The addition of HA to HS was linked to a better tolerability profile. When HS was coupled with HA, there was a reduction in all side effects. This may permit tolerance of the medication in otherwise difficult patients, improve adherence to patients receiving frequent inhalations, and improve therapeutic outcomes. Conclusion The addition of HA is advantageous in CF patients who require continuous HS therapy and have previously shown poor tolerance to therapy.

show abstract

Versatile strategies for bioproduction of hyaluronic acid driven by synthetic biology

Yao

Qin

Gong

et al. 2021

Carbohydrate Polymers

View full text Add to dashboard Cite

The Advantages of Adding Hyaluronic Acid or Mannitol to Hypertonic Saline Inhalation Treatment in Cystic Fibrosis

Cited by 4 publications

References 2 publications

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial

The effectiveness of hyaluronic acid in reducing adverse effects associated with inhaled hypertonic saline therapy in patients with cystic fibrosis: A systematic review and meta-analysis

Versatile strategies for bioproduction of hyaluronic acid driven by synthetic biology

Contact Info

Product

Resources

About